cosentyx 150mg/ml solucion inyectable
novartis biosciences peru s.a. - droguerÍa - secukinumab - solucion inyectable - 150 mg/ml - por jeringa precargada 1.00 ml - - secukinumab
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - inmunosupresores - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriásica arthritiscosentyx, solo o en combinación con metotrexato (mtx), está indicado para el tratamiento de la artritis psoriásica activa en pacientes adultos cuando la respuesta a la anterior modificadores de la enfermedad anti reumáticas de drogas (dmard), la terapia ha sido insuficiente. axial spondyloarthritis (axspa)espondilitis anquilosante (como, radiografía axial spondyloarthritis)cosentyx está indicado para el tratamiento de la espondilitis anquilosante activa en los adultos que han respondido de forma inadecuada a la terapia convencional. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
cosentyx 300mg/2ml solucion inyectable
novartis biosciences peru s.a. - droguerÍa - secukinumab - solucion inyectable - 300 mg/ 2 ml - por jeringa precargada 2.00 ml - - secukinumab
cosentyx 150 mg polvo para solucion inyectable
novartis biosciences peru s.a. - droguerÍa - secukinumab; - polvo para solucion inyectable - por vial 150.00 mg - - secukinumab
doxet 60mg comprimido recubierto
farmindustria s.a. - duloxetina; - comprimido recubierto - por vial150 mg; clorhidrato de duloxetina 67.355000 mg; - secukinumab
cosentyx solución inyectable
scienza uruguay - solución inyectable - secukinumab 150 mg/ml inyectable
tropivac plus capsula blanda
lukoll s.a.c. - capsula blanda - por jeringa prellenada1 ml; estriol 0.200000 mg; lactobacillus casei 341.000000 mg; progesterona 2.000000 mg; - secukinumab
cosentyx 150 mg polvo para solucion inyectable
novartis pharma a.g. suiza - secukinumab (ain457)----150.00 mg - polvo para solucion inyectable - cada vial de polvo contiene: secukinumab (ain457)----150.00 mg
cosentyx 150 mg/ml solución inyectable
novartis pharma a.g. suiza - secukinumab (ain457)----150,0 mg/ml - soluciÓn inyectable - cada mililitro contiene: secukinumab (ain457)----150,0 mg
cosentyx 150 mg/ml solución inyectable
secukinumab - solución inyectable - 150 mg/ml